Neelaveni K, Kumar K V S Hari, Sahay Rakesh, Ramesh Jayanthy
Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India.
Department of Endocrinology, Army Hospital (R and R), New Delhi, India.
Indian J Endocrinol Metab. 2017 Sep-Oct;21(5):699-702. doi: 10.4103/ijem.IJEM_452_16.
Management guidelines about the thyroid disease in pregnancy are silent about the postpartum course of new onset subclinical hypothyroidism (SCH). Hence, we analyzed the 2 years outcome of SCH diagnosed during pregnancy.
We conducted this retrospective study using the medical records of patients with new onset SCH during pregnancy between 2010 and 2013 ( = 718). Patients who stopped their levothyroxine after delivery with a 2-year follow-up record were included. We excluded patients with known thyroid disorders and continuous use of drugs that affect the thyroid results. The patients were divided into two groups (Group 1 - euthyroid and Group 2 - hypothyroid) based on the final outcome after 2 years. The data were analyzed using appropriate statistical methods and a < 0.05 was considered statically significant.
A total of 559 (77.8%) women stopped levothyroxine after delivery, and the final follow-up data were available for 467 patients only. At the end of 2 years, 384 (82.2%) remained euthyroid, and the remaining 83 (17.8%) developed hypothyroidism. SCH and overt hypothyroidism were seen in 22 and 61 patients, respectively. Group 2 patients had higher mean age (25.5 vs. 23.6 years), goiter (51 vs. 2%), initial thyroid stimulating hormone (7.9 vs. 5.1 μIU/mL), and thyroid antibody positivity (76 vs. 13%) ( < 0.001).
The majority of patients with SCH during pregnancy remain euthyroid after delivery. Advanced age, goiter, positive family history, and thyroid autoimmunity increase the future risk of hypothyroidism in patients with SCH diagnosed during pregnancy.
关于孕期甲状腺疾病的管理指南未提及新发亚临床甲状腺功能减退症(SCH)的产后病程。因此,我们分析了孕期诊断出的SCH患者的两年转归情况。
我们利用2010年至2013年间孕期新发SCH患者的病历进行了这项回顾性研究(n = 718)。纳入产后停用左甲状腺素且有两年随访记录的患者。我们排除了已知甲状腺疾病以及持续使用影响甲状腺检查结果药物的患者。根据两年后的最终转归情况,将患者分为两组(第1组 - 甲状腺功能正常组和第2组 - 甲状腺功能减退组)。采用适当的统计方法对数据进行分析,P < 0.05被认为具有统计学意义。
共有559名(77.8%)女性产后停用左甲状腺素,仅467名患者有最终随访数据。两年结束时,384名(82.2%)患者仍甲状腺功能正常,其余83名(17.8%)发展为甲状腺功能减退症。分别有22名和61名患者出现SCH和显性甲状腺功能减退症。第2组患者的平均年龄较高(25.5岁对23.6岁)、有甲状腺肿(51%对2%)、初始促甲状腺激素水平较高(7.9 μIU/mL对5.1 μIU/mL)以及甲状腺抗体阳性率较高(76%对13%)(P < 0.001)。
孕期患有SCH的大多数患者产后仍保持甲状腺功能正常。高龄、甲状腺肿、家族史阳性以及甲状腺自身免疫会增加孕期诊断出的SCH患者未来发生甲状腺功能减退症的风险。